Dedicated to Transformative Cellular Immunotherapies

SenlangBio is a clinical-stage biotechnology company that focuses on three advanced technology platforms—CAR T-cells, CAR-γδ T-cells and armTILs—to develop a robust pipeline of innovative and transformative cellular immunotherapies for cancer patients.

About Us

SenlangBio is a wholly owned subsidiary of Avalon GloboCare Corp. (NASDAQ: AVCO)

First-in-Class CAR-T Technologies

CAR T-Cell Therapy Platform

Chimeric antigen receptor (CAR) T-cells (CAR-T) are natural cell-killing T-cells that have been engineered to specifically recognize and kill cancerous cells.

View Our CAR-T Platform

CAR-GDT (CAR γδT-cell) Therapy Platform

Allogeneic (universal) CAR γδT-cells are a specific class of donor-derived T-cells that can provide superior anti-tumor effectiveness.

View Our CAR-GDT Platform

Tumor Infiltrating Lymphocytes (TILs) Cell Therapy Platform

Armored tumor infiltrating lymphocytes (armTILs) are cancer-killing T-cells that provide a unique “personalized” cellular immunotherapy approach.

View Our TILs Platform

A Diverse and Extensive Cellular Therapeutics Pipeline

Our diverse and comprehensive product pipeline consists of cellular immunotherapy candidates that target multiple types of hematologic and solid tumor malignancies

Learn About Our Pipeline